BioLineRx Ltd.

1.45 USD
+0.02 (+1.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioLineRx Ltd. stock is down -3.33% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 12 November’s closed higher than October. 100% of analysts rate it a buy.

About BioLineRx Ltd.

Motixafortide, a peptide, has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization. It is also developing AGI-134, an immuno-oncology agent, and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.